# Trade Mark Journal No.2026/008 20 February 2026

## WO0000001889680 (5,42)

Office of origin: United States of America

Date of International Registration:8 September 2025
Date of designation in the UK: 8 September 2025

International priority date claimed: 8 August 2025 (United States of America) (99327839)

Class 5
  Pharmaceutical preparations; pharmaceutical preparations for the treatment of cystic fibrosis; pharmaceutical preparations for the treatment of genetic diseases or disorders; pharmaceutical preparations for the treatment of endocrine diseases or disorders; pharmaceutical preparations for the treatment of cellular diseases or disorders; pharmaceutical preparations for the treatment of pulmonary, respiratory, gastrointestinal, digestive, metabolic, and pancreatic diseases or disorders.
Class 42
  Pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; testing of pharmaceuticals; consulting services for others in the field of pharmaceutical research and development; consulting services for others in the field of pharmaceuticals research; research and development in the field of cystic fibrosis; research and development in the field of genetic diseases or disorders; research and development in the field of endocrine diseases or disorders; research and development in the field of cellular diseases or disorders; research and development in the field of pulmonary, respiratory, gastrointestinal, digestive, metabolic, and pancreatic diseases or disorders.

Sionna Therapeutics, Inc.

Representative: Keith Toms, Esq. McCarter & English, LLP, 265 Franklin Street, Boston MA 02110, UNITED STATES OF AMERICA